Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECG Effects of BMS-986165 in Healthy Subjects
NCT03541564Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2018
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of deucravacitinib in systemic lupus erythematosus (SLE) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Placebo-corrected change from baseline in Fridericia QT Interval at 5 days. Started May 2018; status: completed.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT03541564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03541564.